Accessibility Menu

Opus Genetics

(NASDAQ) IRD

Current Price$4.05
Market Cap$336.04MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-32%
5 Year-9%
1 Year+307%
1 Month+1%

Opus Genetics Financials at a Glance

Market Cap

$336.04MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$11.98M

Net Income (TTM)

-$106.93M

EPS (TTM)

-$1.35

P/E Ratio

-3.00

Dividend

$0.00

Beta (Volatility)

1.00 (Low)

Price

$4.05

Volume

1,032,432

Open

$4.11

Previous Close

$4.05

Daily Range

$3.80 - $4.17

52-Week Range

$1.00 - $5.81

Estimated Earnings Date

Aug 12, 2026

IRD News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Opus Genetics

Industry

Biotechnology

Employees

28

CEO

George Magrath, III, MD

Headquarters

Durham, NC 48335, US

IRD Financials

Key Financial Metrics (TTM)

Gross Margin

49.64%

Operating Margin

-359.13%

Net Income Margin

-892.36%

Return on Equity

6068.79%

Return on Capital

-251.49%

Return on Assets

-160.11%

Earnings Yield

-33.33%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$336.04MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

82.57M

Volume

1.03M

Avg. Volume

981.00K

Financials (TTM)

Gross Profit

$5.95M

Operating Income

-$43.03M

EBITDA

-$104.73M

Operating Cash Flow

-$38.99M

Capital Expenditure

$0.00

Free Cash Flow

-$38.99M

Cash & ST Invst.

$59.96M

Total Debt

$25.93M

Opus Genetics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$2.16M

-50.6%

Gross Profit

$2.14M

-50.9%

Gross Margin

99.40%

N/A

Market Cap

$336.04MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$18.67M

N/A

Employees

18

N/A

Net Income

-$65.54M

-699.8%

EBITDA

-$64.87M

-852.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$59.96M

+43.5%

Total Debt

$25.93M

N/A

Accounts Receivable

$2.72M

-42.9%

Inventory

$0.00

N/A

Long Term Debt

$25.93M

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-1.60%

N/A

Return on Invested Capital

-74.91%

N/A

Free Cash Flow

-$12.73M

-41.5%

Operating Cash Flow

-$12.73M

-41.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ALECAlector, Inc.
$1.93-0.52%
ABOSAcumen Pharmaceuticals, Inc.
$2.57-3.75%
AGENAgenus Inc.
$3.50+2.64%
HURATuHURA Biosciences, Inc.
$2.24-5.08%

Trending Stocks

Symbol / CompanyPricePrice Chg
AALAmerican Airlines Group
$17.20-0.03%
RIVNRivian Automotive
$16.49-0.18%
CLROClearOne
$13.84+0.98%
CRNXCrinetics Pharmaceuticals
$83.53+0.99%

Questions About IRD

What is the current price of Opus Genetics?

Opus Genetics is trading at $4.05 per share.

What is the 52-week range for Opus Genetics?

Over the past 52 weeks, Opus Genetics has traded between $1.00 and $5.81.

How much debt does Opus Genetics have?

As of the most recent reporting period, Opus Genetics reported total debt of $25.93M.

How much cash does Opus Genetics have on hand?

Opus Genetics reported $59.96M in cash and cash equivalents in its most recent financial results.

What is Opus Genetics’s dividend yield?

Opus Genetics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.